99 Acquisition Group Stock (NASDAQ: NNAGW)

Latest News for 99 Acquisition Group Stock (NASDAQ:NNAGW)

99 Acquisition Group Inc is a newly organized blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

99 Acquisition Group Inc

Cantor Fitzgerald analyst Yi Fu Lee maintains SoundThinking (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSTI#NASDAQ">SSTI</a>) with a Overweight and lowers the price target from $25 to $20.

News

Price Target

Analyst Ratings

SSTI

Cantor Fitzgerald Maintains Overweight on SoundThinking, Lowers Price Target to $20

Earnings

GALT

Galectin Therapeutics Q1 2024 GAAP EPS $(0.19) Misses $(0.16) Estimate

WIIM

DARE

Dare Bioscience shares are trading higher after Brookline Capital upgraded the stock from Hold to Buy and announced a $3 price target.

Stifel analyst Bert Subin maintains Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) with a Buy and maintains $240 price target.

Stifel Maintains Buy on Boeing, Maintains $240 Price Target

ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.18) by 5.56 percent. This is a 19.05 percent increase over losses of $(0.21) per share from the same period last year.

ATAI

ATAI Life Sciences Q1 EPS $(0.17) Beats $(0.18) Estimate, Cash $18.87M

Jack In The Box Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) reported better-than–expected second-quarter FY24 <a href="https://www.benzinga.com/news/earnings/24/05/38820251/fast-food-feast-jack-in-the-boxs-ceo-dishes-out-strategy-amid-q2-ups-and-downs">adjusted EPS on Tuesday</a>.
The company reported a second-quarter FY24 sales decline of 7.7% year-on-year to $365.35 million, missing the analyst consensus estimate of $368.64 million. Adjusted EPS of $1.46 beat the consensus estimate of $1.42, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Jack In The Box same-store sales decreased 2.5% in the second quarter, consisting of a decline in company-operated same-store sales of 0.6% and a decrease in franchise same-store sales of 2.6%. Systemwide sales for the quarter dropped 1.6%.
"I am proud of the execution by our Jack and Del Taco teams, delivering better-than-expected earnings and margin performance while navigating through increasing macro headwinds, pressure on low-income consumers and the implementation of California's minimum wage legislation," said CEO Darin Harris. "Top-line performance was impacted by the shift in consumer behavior and an unexpected delay in our Smashed Jack launch, but sales have improved since its introduction in mid-March. We have a clear plan to regain same store sales traction through a strong marketing calendar, new LTO's, and an expanded value menu throughout the remainder of 2024."
Jack In The Box slashed the upper end of its FY24 EPS outlook, revising the range from $6.25 – $6.50 to $6.25 – $6.40. The company now sees FY24 adjusted EBITDA of $325 million – $330 million (previously $325 million – $335 million).
Jack In The Box shares closed at $53.07 on Tuesday.
These analysts made changes to their price targets on Jack In The Box after the company reported quarterly results.
<ul>
<li>Wedbush cut the price target on Jack In The Box from $78 to $68. Wedbush analyst Nick Setyan maintained an Outperform rating.</li>
<li>TD Cowen slashed Jack In The Box price target from $73 to $59. TD Cowen analyst Andrew Charles maintained a Hold rating.</li>
<li>B of A Securities slashed the price target on Jack In The Box from $87 to $83. B of A Securities analyst Sara Senatore maintained a Buy rating.</li>
<li>Morgan Stanley lowered the price target on Jack In The Box from $75 to $70. Morgan Stanley analyst John Glass maintained an Equal-Weight rating.</li>
</ul>
Read More: <a href="https://www.benzinga.com/news/24/05/38837718/dlocal-allogene-therapeutics-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session">DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday&#8217;s Pre-Market Session</a>

Markets

Trading Ideas

JACK

Jack In The Box Analysts Cut Their Forecasts After Q2 Results

<ul>
<li>Paragon will provide the Company with an exclusive license to its patents covering the related antibody, the method of use and its method of manufacture.</li>
<li>Paragon will not conduct any new campaigns that generate anti-&alpha;4&szlig;7 or anti-TL1A monospecific antibodies for at least 5 years.</li>
<li>The Company will pay Paragon a low single-digit percentage royalty for single antibody products and a mid single-digit percentage royalty for products containing more than one antibody from Paragon.</li>
<li>There is a royalty step-down of 1/3rd if there is no Paragon patent in effect during the royalty term.</li>
<li>The royalty term ends on the later of (i) the last-to-expire licensed patent or Company patent directed to a derived antibody or (ii) 12 years from the date of first sale of a Company product.</li>
<li>Agreement may be terminated on 60 days&rsquo; notice by the Company; on material breach without cure; and to the extent permitted by law, on a party&rsquo;s insolvency or bankruptcy.</li>
<li>With respect to the SPY002 License Agreement only, on a product by product basis, the Company will pay Paragon sublicensing fees of up to approximately $20 million upon the achievement of mostly commercial milestones.&nbsp;</li>
</ul>

Biotech

Health Care

Contracts

General

SYRE

On May 14, 2024, Paragon Therapeutics Announced A License Agreement Granting Spyre Therapeutics An Exclusive License To Certain Antibodies And Products Targeting α4SS7 Integrin And Tl1A, Paragon Will Up To $22M In Milestone Payments-8K

LILM

The Federal Government Of Germany And The Free State Of Bavaria Have Commissioned The State Development Bank Kfw In Frankfurt To Conduct Due Diligence On Lilium As Part Of The Customary State Support Process

Guidance

SYPR

Sypris Solutions Updated Its Full-year Outlook For 2024, Maintaining The Expected Increase In Revenue At 10%-15% YoY, While Adjusting The Gross Margin Guidance To A 100-125 Basis Point Increase

FRZA

Forza X1 shares are trading lower. The company reported Q1 financial results.

Benchmark analyst Robert Wasserman reiterates Nephros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEPH#NASDAQ">NEPH</a>) with a Speculative Buy and maintains $5 price target.

Reiteration

NEPH

Benchmark Reiterates Speculative Buy on Nephros, Maintains $5 Price Target

Stifel analyst Erik Rasmussen maintains Terran Orbital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLAP#NYSE">LLAP</a>) with a Buy and maintains $7 price target.

LLAP

Stifel Maintains Buy on Terran Orbital, Maintains $7 Price Target

Stifel analyst Stephen Gengaro maintains Smart Sand (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SND#NASDAQ">SND</a>) with a Hold and maintains $3 price target.

Stifel Maintains Hold on Smart Sand, Maintains $3 Price Target

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a <a href="https://www.benzinga.com/yield-investments">high dividend payout</a>. 
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a> .
Below are the ratings of the most accurate analysts for three high-yielding stocks in the materials sector.
<h3 class="wp-block-heading">Kronos Worldwide, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRO#NYSE">KRO</a>)</h3>
<ul>
<li>Dividend Yield: 6.06%</li>
<li>Barclays analyst Michael Leithead maintained an Underweight rating and raised the price target from $7 to $8 on March 26. This analyst has an accuracy rate of 65%.</li>
<li>Deutsche Bank analyst David Begleiter maintained a Buy rating and cut the price target from $12 to $11 on May 22, 2023. This analyst has an accuracy rate of 75%.</li>
<li>Recent News: On May 8, Kronos Worldwide posted better-than-expected quarterly earnings.</li>
</ul>
<h3 class="wp-block-heading">Compass Minerals International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>)</h3>
<ul>
<li>Dividend Yield: 4.74%</li>
<li>JP Morgan analyst JeffreyZekauskasmaintained a Neutral rating and cut the price target from $24 to $21 on Feb. 9. This analyst has an accuracy rate of 71%.</li>
<li>Stifel analyst Vincent Andersonmaintained a Buy rating and slashed the price target from $75 to $60 on Jan. 11. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: On May 7, Compass Minerals Intl reported second-quarter financial results and issued FY24 revenue guidance below estimates..</li>
</ul>
<h3 class="wp-block-heading">Huntsman Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUN#NYSE">HUN</a>)</h3>
<ul>
<li>Dividend Yield: 3.97%</li>
<li>Wells Fargo analyst Michael Sisonupgraded the stock from Equal-Weight to Overweight &nbsp;on Feb. 23. This analyst has an accuracy rate of 72%.</li>
<li>Stifel analyst Vincent Andersonmaintained a Buy rating and lowered the price target from $30 to $29 on Jan. 24. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: On May 2, Huntsman posted weak quarterly sales.</li>
</ul>
Read More: <a href="https://www.benzinga.com/news/earnings/24/05/38835382/investor-optimism-improves-ahead-of-cpi-report-nasdaq-settles-at-record-high">Investor Optimism Improves Ahead Of CPI Report, Nasdaq Settles At Record High</a>

Dividends

Pre-Market Outlook

Wall Street's Most Accurate Analysts' Views On 3 Materials Stocks Delivering High-Dividend Yields

Benchmark analyst John Lawrence maintains Boot Barn Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) with a Buy and raises the price target from $88 to $110.

BOOT

Benchmark Maintains Buy on Boot Barn Holdings, Raises Price Target to $110

Stifel analyst Benjamin Nolan maintains Seadrill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDRL#NYSE">SDRL</a>) with a Buy and maintains $73 price target.

SDRL

Stifel Maintains Buy on Seadrill, Maintains $73 Price Target

LIDR

AEye shares are trading lower after the company reported worse-than-expected Q1 sales results.

Sypris Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYPR#NASDAQ">SYPR</a>) reported quarterly losses of $(0.10) per share. This is a 900 percent decrease over losses of $(0.01) per share from the same period last year. The company reported $35.55 million in sales this quarter. This is a 10.10 percent increase over sales of $32.29 million the same period last year.

Sypris Solutions Q1 EPS $(0.10) Down From $(0.01) YoY, Sales $35.55M Up From $32.29M YoY

Stifel analyst Bert Subin maintains Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) with a Buy and maintains $25 price target.

SNDR

Stifel Maintains Buy on Schneider National, Maintains $25 Price Target

Stifel analyst Benjamin Burnett maintains Precigen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>) with a Buy and maintains $7 price target.